The short version of GHK sequence fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide sequence is often abbreviated Gly-His-Lys, and the copper is bound through the histidine imidazole nitrogen and adjacent peptide nitrogens. The complex is frequently described as a 1:1 peptide-to-copper species. It occurs naturally in human plasma, saliva, and urine at low concentrations. Its endogenous levels have been reported to decline with age, although the precise physiological role of that change remains an open question.
Research interest in GHK-Cu centers on its ability to deliver copper and to influence cellular processes in laboratory models. In cell culture and animal studies, the complex has been linked to collagen synthesis, antioxidant enzyme activity, and expression of genes associated with tissue remodeling. These effects are not equivalent to proven clinical outcomes. The mechanisms proposed include copper transfer to cuproenzymes, modulation of growth factor signaling, and interactions with extracellular matrix components. How much of the observed activity depends on intact GHK-Cu versus free copper or free peptide is not fully resolved.
The compound entered scientific literature in the 1970s, when plasma factors with copper-binding activity were isolated and characterized. Later work expanded into wound healing, skin biology, and cosmetic formulation, where copper tripeptide-1 became a recognized ingredient name. Most published studies remain preclinical or small-scale, and findings are often reported in specialized dermatology or peptide journals. Regulatory treatment varies: some jurisdictions allow it as a cosmetic ingredient, while research-grade material is sold for laboratory use. Questions about optimal delivery, target tissues, and long-term effects continue to be investigated rather than settled.
The tripeptide was first isolated from a human plasma filtrate in 1973 during studies of tissue repair factors. Later work detected the free peptide and its copper complex in saliva, urine, and wound fluid, suggesting a natural role in tissue remodeling. Plasma concentrations reported in early literature decline with age, a pattern often cited in discussions of skin aging. Whether these endogenous levels are directly functional or largely incidental remains an open question. The peptide sequence is conserved across mammalian species.
Material described in research and cosmetic supply chains is typically a synthetic peptide supplied as a lyophilized powder. Purity is commonly reported through chromatographic separation, often at 95 percent or higher, while copper content is confirmed by separate elemental analysis. Batch variation in color and solubility can reflect residual counter-ions, moisture, or partial oxidation of the peptide. Because the complex is not a single regulatory entity, specifications differ between suppliers and are not standardized internationally.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Copper-binding tripeptide complex | Includes Gly-His-Lys and Cu(II) |
| Molecular formula | C14H22CuN6O4 | Reported for the 1:1 complex |
| Appearance | Blue to blue-violet solid | Color arises from copper d-d transitions |
| Solubility class | Water-soluble; slightly soluble in polar organic solvents | Often prepared as aqueous stock |
| Typical storage | -20 °C, desiccated, protected from light | Limits oxidation and moisture uptake |
Mechanistic accounts focus on how the complex delivers copper and how the released peptide interacts with the extracellular matrix. Copper is an essential cofactor for lysyl oxidase and other enzymes involved in collagen and elastin cross-linking, and GHK is one of several peptides able to carry the metal. Reported effects include altered gene expression in fibroblasts and changes in matrix metalloproteinase activity, although many of these findings come from cell culture rather than whole organisms. The relative contribution of the peptide backbone, the copper ion, and downstream copper metabolism is not fully resolved.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-lysine and a copper(II) ion. The peptide sequence is conventionally written as Gly-His-Lys, abbreviated GHK. Copper binds through the imidazole nitrogen of histidine, the alpha-amino group, and a deprotonated amide nitrogen, producing a square-planar geometry. The complex carries a net positive charge near physiological pH and is intensely blue in aqueous solution. The metal-free peptide is often written simply as GHK, while the copper-bound form is written GHK-Cu.
The compound was first isolated from human plasma by the biochemist Loren Pickart in 1973. Early work identified it as a factor that altered the behavior of cultured liver cells, and later studies linked it to connective tissue and wound-related processes. Reported plasma concentrations fall markedly between roughly age twenty and age sixty, a pattern that generated interest in copper peptide biology. Whether that decline has functional consequences remains an open question, because differences observed across age groups do not by themselves establish causation. Research interest later expanded into cosmetic and tissue-culture settings.
The peptide portion consists of three amino acids: glycine, histidine and lysine. Copper(II) coordinates through the imidazole nitrogen of histidine, the alpha-amino group of glycine and a deprotonated amide nitrogen of the backbone, producing a roughly square-planar geometry. This arrangement gives the complex its characteristic blue-to-violet colour and helps it resist dissociation in water. Reported stability constants are high, although values differ between studies because of differences in ionic strength and measurement method.
The International Nomenclature of Cosmetic Ingredients lists the substance as copper tripeptide-1, the name that appears on most topical product labels. Related designations include copper peptide and GHK-Cu, and the hyphenated form is common in research literature. In cosmetics the material is regulated as an ingredient rather than as a drug, so products may reach the market without evidence of the effects claimed for them. Whether those effects are clinically meaningful is an open question, since most supportive data come from laboratory work and small trials.
GHK-Cu is a coordination complex formed between the peptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The unbound chain, abbreviated GHK, consists of three amino acids and occurs naturally in human plasma, saliva, and urine. Binding of the metal is mediated mainly by the imidazole nitrogen of the histidine residue together with backbone amides, producing a stable chelate. Ingredient nomenclature often lists the same substance as copper tripeptide-1. Its charge and solubility behaviour differ from those of the metal-free chain.
The copper-binding activity of this sequence was described in the 1970s during studies of liver tissue and plasma factors. Early work identified the peptide as a component that influenced copper uptake by cells and that appeared in wound fluid. Later investigations examined its presence across species, reporting the same chain in human and animal samples. A decline in measured concentration with age became a recurring observation, although the underlying causes remain incompletely characterised.
=== EC 2.3.2: Aminoacyltransferases === EC 2.3.2.1: D-glutamyltransferase EC 2.3.2.2: γ-glutamyltransferase EC 2.3.2.3: lysyltransferase EC 2.3.2.4: Now classified as EC 4.3.2.9, γ-glutamylcyclotransferase EC 2.3.2.5: glutaminyl-peptide cyclotransferase EC 2.3.2.6: leucyltransferase EC 2.3.2.7: aspartyltransferase EC 2.3.2.8: arginyltransferase EC 2.3.2.9: agaritine γ-glutamyltransferase EC 2.3.2.10: UDP-N-acetylmuramoylpentapeptide-lysine N6-alanyltransferase EC 2.3.2.11: alanylphosphatidylglycerol synthase EC 2.3.2.12: peptidyltransferase EC 2.3.2.13: protein-glutamine g-glutamyltransferase EC 2.3.2.14: D-alanine γ-glutamyltransferase EC 2.3.2.15: glutathione γ-glutamylcysteinyltransferase EC 2.3.2.16: lipid II:glycine glycyltransferase EC 2.3.2.17: N-acetylmuramoyl-L-alanyl-D-glutamyl-L-lysyl-(N6-glycyl)-D-alanyl-D-alanine-diphosphoundecaprenyl-N-acetylglucosamine:glycine glycyltransferase EC 2.3.2.18: N-acetylmuramoyl-L-alanyl-D-glutamyl-L-lysyl-(N6-triglycine)-D-alanyl-D-alanine-diphosphoundecaprenyl-N-acetylglucosamine:glycine glycyltransferase EC 2.3.2.19: ribostamycin:4-(γ-L-glutamylamino)-(S)-2-hydroxybutanoyl-[BtrI acyl-carrier protein] 4-(γ-L-glutamylamino)-(S)-2-hydroxybutanoate transferase EC 2.3.2.20: cyclo(L-leucyl-L-phenylalanyl) synthase EC 2.3.2.21: cyclo(L-tyrosyl-L-tyrosyl) synthase EC 2.3.2.22: cyclo(L-leucyl-L-leucyl) synthase EC 2.3.2.23: E2 ubiquitin-conjugating enzyme EC 2.3.2.24: (E3-independent) E2 ubiquitin-conjugating enzyme EC 2.3.2.25: N-terminal E2 ubiquitin-conjugating enzyme EC 2.3.2.26: HECT-type E3 ubiquitin transferase EC 2.3.2.27: RING-type E3 ubiquitin transferase EC 2.3.2.28: L-allo-isoleucyltransferase EC 2.3.2.29: aspartate/glutamate leucyltransferase EC 2.3.2.30: L-ornithine Nα-acyltransferase EC 2.3.2.31: RBR-type E3 ubiquitin transferase EC 2.3.2.32: cullin-RING-type E3 NEDD8 transferase EC 2.3.2.33: RCR-type E3 ubiquitin transferase EC 2.3.2.34: E2 NEDD8-conjugating enzyme EC 2.3.2.35: capsaicin synthase EC 2.3.2.36: RING-type E3 ubiquitin transferase (cysteine targeting)
=== Substrate-like inhibitors === Substrate-like inhibitors (Figure 4) are more common than the non-substrate-likes. They bind either covalently or non-covalently and have a basic structure where the P1-substituent occupies the S1-pocket and the P2-substituent occupies the S2-pocket. Usually they contain a proline mimetic that occupies the S1-pocket. Large substituents on the 2-cyanopyrrolidine ring are normally not tolerated since the S1-pocket is quite small. Since DPP-4 is identical with the T-cell activation marker CD26 and DPP-4 inhibitors are known to inhibit T-cell proliferation, these compounds were initially thought to be potential immunomodulators. When the function against type 2 diabetes was discovered, the cyanopyrrolidines became a highly popular research material. A little later vildagliptin and saxagliptin, which are the most developed cyanopyrrolidine DPP-4 inhibitors to date, were discovered.
==== Species ==== The genus includes dog violets, a group of scentless species which are the most common Viola in many areas, sweet violet (Viola odorata) (named from its sweet scent), and many other species whose common name includes the word "violet". But not other "violets": Neither Streptocarpus sect. Saintpaulia ("African violets", Gesneriaceae) nor Erythronium dens-canis ("dogtooth violets", Liliaceae) are related to Viola.
==== Combinatorial probe anchor synthesis (cPAS) ==== This method is an upgraded modification to combinatorial probe anchor ligation technology (cPAL) described by Complete Genomics which has since become part of Chinese genomics company BGI in 2013. The two companies have refined the technology to allow for longer read lengths, reaction time reductions and faster time to results. In addition, data are now generated as contiguous full-length reads in the standard FASTQ file format and can be used as-is in most short-read-based bioinformatics analysis pipelines. The two technologies that form the basis for this high-throughput sequencing technology are DNA nanoballs (DNB) and patterned arrays for nanoball attachment to a solid surface. DNA nanoballs are simply formed by denaturing double stranded, adapter ligated libraries and ligating the forward strand only to a splint oligonucleotide to form a ssDNA circle. Faithful copies of the circles containing the DNA insert are produced utilizing Rolling Circle Amplification that generates approximately 300–500 copies. The long strand of ssDNA folds upon itself to produce a three-dimensional nanoball structure that is approximately 220 nm in diameter. Making DNBs replaces the need to generate PCR copies of the library on the flow cell and as such can remove large proportions of duplicate reads, adapter-adapter ligations and PCR induced errors.
Sources: en.wikipedia.org
Psychedelic microdosing is the practice of using sub-threshold doses (microdoses) of psychedelics in an attempt to improve creativity, boost physical energy level, emotional balance, increase performance on problems-solving tasks and to treat anxiety, depression and addiction. The practice of microdosing has become more widespread in the 21st century with more people claiming long-term benefits from the practice. A 2022 study recognized signatures of psilocybin microdosing in natural language and concluded that low amount of psychedelics have potential for application, and ecological observation of microdosing schedules.
Cronulla-Sutherland Sharks supplements saga Drugs in the Australian Football League Drugs in sport in Australia List of Australian sports controversies List of doping cases in sport (E) List of sporting scandals
=== Neurology and cardiology === Theranostics extends beyond oncology and holds potential in the fields of neurology and cardiology. In neurology, theranostic approaches offer new avenues for the diagnosis and treatment of various neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Advanced imaging techniques, including magnetic resonance imaging (MRI) and positron emission tomography (PET), allow for the visualization of neuroanatomy, functional connectivity, and molecular changes in the brain. This enables early detection, precise diagnosis, and monitoring of disease progression, facilitating the development of targeted therapeutic interventions. Similarly, in cardiology, theranostics play a significant role in the diagnosis and treatment of cardiovascular conditions. Non-invasive imaging modalities like MRI and computed tomography (CT) provide detailed information about cardiac structure, function, and blood flow, aiding in the assessment of heart disease and the guidance of interventions. Theranostic approaches in cardiology involve targeted drug delivery systems for the treatment of conditions such as atherosclerosis and restenosis, as well as image-guided interventions for precise stenting or catheter-based therapies.
== Reactivity == Ninhydrin exists in equilibrium with the triketone indane-1,2,3-trione, which reacts readily with nucleophiles (including water). Whereas for most carbonyl compounds, a carbonyl form is more stable than a product of water addition (hydrate), ninhydrin forms a stable hydrate of the central carbon because of the destabilizing effect of the adjacent carbonyl groups. To generate the ninhydrin chromophore [2-(1,3-dioxoindan-2-yl)iminoindane-1,3-dione], the amine must condense to give a Schiff base. The reaction of ninhydrin with secondary amines gives an iminium salt, which is also coloured, generally being yellow–orange.
=== Boxed warning === "Paracetamol has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of paracetamol at doses that exceed 4000 milligrams per day, and often involve more than one paracetamol-containing product." In the US, the label for hydrocodone/paracetamol contains a boxed warning about addiction, abuse, and misuse.
Sources: en.wikipedia.org
Elected to the U.S. Senate in 1972, Biden was reelected in 1978, 1984, 1990, 1996, 2002, and 2008, regularly receiving about 60% of the vote. Aged 30 when first elected, he was the seventh-youngest senator in U.S. history. He was junior senator to William Roth until Roth was defeated in 2000. He remains one of the longest-serving senators in U.S. history. For 36 years, he commuted from Washington to Wilmington via Amtrak, earning him the nickname "Amtrak Joe".
==== Recurrent psychotic episodes ==== Placebo-controlled trials of both first- and second-generation antipsychotic drugs consistently demonstrate the superiority of active drugs over placebos in suppressing psychotic symptoms. A large meta-analysis of 38 trials of antipsychotic drugs in schizophrenia with acute psychotic episodes showed an effect size of about 0.5. There is little or no difference in efficacy among approved antipsychotic drugs, including both first- and second-generation agents. The efficacy of such drugs is suboptimal. Few patients achieve complete resolution of symptoms. Response rates, calculated using various cutoff values for symptom reduction, are low, and their interpretation is complicated by high placebo response rates and selective publication of clinical trial results.
=== Lactation === Prolactin is the primary lactogenic hormone. It drives mammary gland development (mammogenesis), milk synthesis (lactogenesis), and maintenance of milk production. PRLR-knockout mice show absent mammary development. During pregnancy, high estrogen and progesterone promote ductal and lobuloalveolar growth but suppress milk secretion; withdrawal of these steroids at parturition permits prolactin-driven lactogenesis. Suckling activates a neuroendocrine reflex: afferent signals from mechanoreceptors inhibit TIDA dopamine release (raising prolactin) while simultaneously triggering oxytocin release for the milk ejection reflex.
=== 2020 census === As of the 2020 census, Lebanon had a population of 16,662. The median age was 39.1 years. 22.4% of residents were under the age of 18 and 18.0% of residents were 65 years of age or older. For every 100 females there were 95.6 males, and for every 100 females age 18 and over there were 91.8 males age 18 and over. 97.2% of residents lived in urban areas, while 2.8% lived in rural areas. There were 7,045 households in Lebanon, of which 28.2% had children under the age of 18 living in them. Of all households, 41.2% were married-couple households, 19.8% were households with a male householder and no spouse or partner present, and 29.6% were households with a female householder and no spouse or partner present. About 33.1% of all households were made up of individuals and 13.4% had someone living alone who was 65 years of age or older. There were 7,563 housing units, of which 6.8% were vacant. The homeowner vacancy rate was 1.5% and the rental vacancy rate was 6.5%.
Sources: en.wikipedia.org
GHK-Cu is a complex of the tripeptide glycyl-L-histidyl-L-lysine with copper(II). The peptide binds copper through its histidine residue and neighboring amide nitrogens, forming a stable coordination compound. It is studied as a research chemical and used in some cosmetic formulations.
Yes, the peptide and its copper complex have been detected in human plasma, saliva, and urine. Endogenous concentrations are low, and reported levels change with age and physiological state. The biological significance of those changes is still an active area of study.
GHK refers to the free tripeptide without a bound copper ion. GHK-Cu contains copper(II) coordinated to the same peptide backbone. The presence of copper affects the complex's color, stability, and interaction with biological molecules.
It is a complex of the tripeptide glycyl-L-histidyl-L-lysine with a copper(II) ion. The peptide coordinates the metal through its histidine, amino terminus, and an amide nitrogen. It is often listed simply as copper tripeptide-1.